B Ettinger

Summary

Publications

  1. ncbi request reprint Rationale for use of lower estrogen doses for postmenopausal hormone therapy
    Bruce Ettinger
    156 Lombard Street 13, San Francisco, CA 94111, USA
    Maturitas 57:81-4. 2007
  2. doi request reprint Proposed pathogenesis for atypical femoral fractures: Lessons from materials research
    B Ettinger
    Department of Medicine, University of California Medical Center, San Francisco, CA, 156 Lombard Street 13, San Francisco, CA 94111, USA Electronic address
    Bone 55:495-500. 2013
  3. pmc Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study
    B Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    Osteoporos Int 24:1185-93. 2013
  4. pmc Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study
    Bruce Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    J Clin Densitom 15:334-42. 2012
  5. doi request reprint Evolution of postmenopausal hormone therapy between 2002 and 2009
    Bruce Ettinger
    University of California, San Francisco, CA, USA
    Menopause 19:610-5. 2012
  6. doi request reprint A personal perspective on fracture risk assessment tools
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 15:1023-6. 2008
  7. doi request reprint Endometrial effects of tibolone in elderly, osteoporotic women
    Bruce Ettinger
    University of California, San Francisco, San Francisco, California, USA
    Obstet Gynecol 112:653-9. 2008
  8. pmc Updated fracture incidence rates for the US version of FRAX
    B Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA
    Osteoporos Int 21:25-33. 2010
  9. ncbi request reprint Initiation of osteoporosis treatment after bone mineral density testing
    A Pressman
    Division of Research, Kaiser Permanente Medical Care Program, 3505 Broadway, Oakland, CA 94611 5714, USA
    Osteoporos Int 12:337-42. 2001
  10. ncbi request reprint Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    B Ettinger
    Division of Research, Kaiser Permanente, Oakland, Calif 94611 5400, USA
    JAMA 282:637-45. 1999

Detail Information

Publications38

  1. ncbi request reprint Rationale for use of lower estrogen doses for postmenopausal hormone therapy
    Bruce Ettinger
    156 Lombard Street 13, San Francisco, CA 94111, USA
    Maturitas 57:81-4. 2007
    ....
  2. doi request reprint Proposed pathogenesis for atypical femoral fractures: Lessons from materials research
    B Ettinger
    Department of Medicine, University of California Medical Center, San Francisco, CA, 156 Lombard Street 13, San Francisco, CA 94111, USA Electronic address
    Bone 55:495-500. 2013
    ....
  3. pmc Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study
    B Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    Osteoporos Int 24:1185-93. 2013
    ..We evaluated performance of FRAX in older men who participated in the Osteoporotic Fractures in Men (MrOS) study...
  4. pmc Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study
    Bruce Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    J Clin Densitom 15:334-42. 2012
    ..01) for major osteoporotic fracture. We conclude that the FRC calibrates well with hip and major osteoporotic fractures observed among older men. Further, addition of BMD to the fracture risk calculation improves the tool's performance...
  5. doi request reprint Evolution of postmenopausal hormone therapy between 2002 and 2009
    Bruce Ettinger
    University of California, San Francisco, CA, USA
    Menopause 19:610-5. 2012
    ..The objective of this analysis was to assess trends in nationwide hormone therapy prescription claims from 2002 to 2009...
  6. doi request reprint A personal perspective on fracture risk assessment tools
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 15:1023-6. 2008
    ..Much more than risk numbers are needed, and, ideally, fracture risk tools should be integrated into bone densitometry reporting or placed into comprehensive, user-friendly, decision aids...
  7. doi request reprint Endometrial effects of tibolone in elderly, osteoporotic women
    Bruce Ettinger
    University of California, San Francisco, San Francisco, California, USA
    Obstet Gynecol 112:653-9. 2008
    ..To investigate endometrial effects of tibolone administered to postmenopausal women for 3 years...
  8. pmc Updated fracture incidence rates for the US version of FRAX
    B Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA
    Osteoporos Int 21:25-33. 2010
    ..On the basis of updated fracture and mortality data, we recommend that the base population values used in the US version of FRAX be revised. The impact of suggested changes is likely to be a lowering of 10-year fracture probabilities...
  9. ncbi request reprint Initiation of osteoporosis treatment after bone mineral density testing
    A Pressman
    Division of Research, Kaiser Permanente Medical Care Program, 3505 Broadway, Oakland, CA 94611 5714, USA
    Osteoporos Int 12:337-42. 2001
    ..Health care providers must consider whether test results will influence treatment decisions, and our data indicate that results of BMD testing do influence management decisions regarding osteoporosis drug use for women...
  10. ncbi request reprint Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    B Ettinger
    Division of Research, Kaiser Permanente, Oakland, Calif 94611 5400, USA
    JAMA 282:637-45. 1999
    ..Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known...
  11. ncbi request reprint Risk for fracture in women with low serum levels of thyroid-stimulating hormone
    D C Bauer
    University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105, USA
    Ann Intern Med 134:561-8. 2001
    ..Use of thyroid hormone itself does not increase risk for fracture if TSH levels are normal...
  12. ncbi request reprint Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs
    B Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, 3505 Broadway, 7th Floor, Oakland, CA 94611 5714, USA
    Am J Manag Care 7:597-605. 2001
    ..To investigate use of osteoporosis drugs among patients with high exposure to glucocorticoid drugs...
  13. ncbi request reprint Low-dosage esterified estrogens opposed by progestin at 6-month intervals
    B Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California 94611 5463, USA
    Obstet Gynecol 98:205-11. 2001
    ....
  14. ncbi request reprint Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy
    B Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA
    Am J Manag Care 5:779-85. 1999
    ..To determine possible differences in continuation of postmenopausal estrogen replacement therapy among women initiating treatment with transdermal estradiol versus those initiating treatment with oral estrogen...
  15. doi request reprint The impact of subtrochanteric fracture criteria on hip fracture classification
    S Y Huang
    Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA
    Osteoporos Int 23:743-50. 2012
    ..Identification of subtrochanteric fractures requires review of radiographic images to distinguish these fractures from the more commonly occurring trochanteric fractures...
  16. ncbi request reprint First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization
    J V Selby
    Division of Research, Kaiser Permanente Medical Care Program Northern California Region, Oakland, USA
    Diabetes Care 22:38-44. 1999
    ....
  17. ncbi request reprint Concomitant medication use in postmenopausal women using estrogen therapy
    R Small
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California 94611-5714, USA
    Menopause 8:120-6. 2001
    ..CONCLUSION: Greater use of certain prescription medications by estrogen users than by nonusers should be considered in studying the health effects of estrogen replacement therapy...
  18. ncbi request reprint Comparison of methods to measure low serum estradiol levels in postmenopausal women
    Jennifer S Lee
    San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
    J Clin Endocrinol Metab 91:3791-7. 2006
    ..Accurate measurement of low serum estradiol (E(2) < 30 pg/ml or < 110 pmol/liter) is needed to study relationships between endogenous E(2) and risks of diseases in older women...
  19. pmc The effects of tibolone in older postmenopausal women
    Steven R Cummings
    San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
    N Engl J Med 359:697-708. 2008
    ..Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain...
  20. ncbi request reprint Persistence with weekly alendronate therapy among postmenopausal women
    J C Lo
    Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA 94612, USA
    Osteoporos Int 17:922-8. 2006
    ..Although clinical trials indicate that oral bisphosphonates reduce osteoporotic fracture risk, compliance with bisphosphonate therapy in practice is suboptimal, with 1-year discontinuation rates exceeding 50%...
  21. ncbi request reprint Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen
    J Kayser
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California 94611, USA
    Menopause 8:328-32. 2001
    ....
  22. ncbi request reprint Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women
    Alison J Huang
    Veterans Affairs Medical Center, San Francisco, California, USA
    J Bone Miner Res 22:1791-7. 2007
    ..This suggests that the protective effects of ultra-low-dose estrogen therapy on the postmenopausal skeletal health may depend critically on women's endogenous estrogen levels before treatment...
  23. ncbi request reprint When is it appropriate to prescribe postmenopausal hormone therapy?
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 13:404-10. 2006
    ..To develop evidence and consensus-based recommendations for the use of hormone therapy (HT) in postmenopausal women...
  24. ncbi request reprint Outcomes of a disease-management program for patients with recent osteoporotic fracture
    M Che
    Department of Medicine, Kaiser Permanente Medical Center, 3700 Vaca Valley Parkway, Vacaville, CA 95688 9430, USA
    Osteoporos Int 17:847-54. 2006
    ....
  25. ncbi request reprint Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Womens Health (Larchmt) 14:159-71. 2005
    ..To devise, validate, and test a software model that improves how clinicians calculate individual risk for osteoporotic fracture and expected treatment benefit...
  26. ncbi request reprint Tibolone for prevention and treatment of postmenopausal osteoporosis
    Bruce Ettinger
    156 Lombard Street 13, San Francisco, CA 94111, USA
    Maturitas 57:35-8. 2007
    ..Now that fracture efficacy has been added to the list of tibolone's documented bone benefits, physicians must consider this in the overall risks and benefits of its use...
  27. ncbi request reprint Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Bone Miner Res 19:745-51. 2004
    ..Conversely, previous alendronate treatment reduced the bone marker and BMD response...
  28. ncbi request reprint Predictors of difficulty when discontinuing postmenopausal hormone therapy
    Deborah Grady
    Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
    Obstet Gynecol 102:1233-9. 2003
    ..To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop...
  29. ncbi request reprint Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial
    Jeffrey A Tice
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco 94143, USA
    JAMA 290:207-14. 2003
    ..Dietary supplements containing isoflavones are widely used as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting their efficacy...
  30. ncbi request reprint Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation
    Deborah Grady
    University of California San Francisco, 1634 Divisadero Street, Suite 600, San Francisco, CA 94115, USA
    Obstet Gynecol 104:837-44. 2004
    ..To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen...
  31. ncbi request reprint Making the most of managed care dollars spent for postmenopausal osteoporosis
    Bruce Ettinger
    Department of Medicine, School of Medicine, University of California, San Francisco, USA
    Manag Care Interface 18:55-9. 2005
    ....
  32. ncbi request reprint Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    Obstet Gynecol 104:443-51. 2004
    ....
  33. ncbi request reprint Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy
    Bruce Ettinger
    Division of Research, Kaiser Permanente Northern California, Oakland, Oakland, California 94611 5714, USA
    Obstet Gynecol 102:1225-32. 2003
    ....
  34. ncbi request reprint Hormone predictors of bone mineral density changes during the menopausal transition
    MaryFran R Sowers
    Department of Epidemiology, School of Public Health, University of Michigan, 339 East Liberty Street, Suite 310, Ann Arbor, MI 48104, USA
    J Clin Endocrinol Metab 91:1261-7. 2006
    ..OBJECTIVE AND CONTEXT: Our objective was to examine predictability of reproductive hormone concentrations for bone mineral density (BMD) loss during the menopausal transition...
  35. ncbi request reprint Early discontinuation of treatment for osteoporosis
    Anna N A Tosteson
    Department of Medicine, Dartmouth Medical School, Hannover, New Hampshire 03756, USA
    Am J Med 115:209-16. 2003
    ..To identify factors associated with early treatment discontinuation of three agents commonly prescribed for women with low bone density...
  36. ncbi request reprint Vasomotor symptom relief versus unwanted effects: role of estrogen dosage
    Bruce Ettinger
    Am J Med 118:74-8. 2005
    ..Furthermore, healthcare providers need to learn how and when to prescribe lower dosages of HT to optimize patient acceptance and continuation...
  37. ncbi request reprint Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol
    Susan R Johnson
    Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City 52242, USA
    Obstet Gynecol 105:779-87. 2005
    ..To investigate uterine effects of unopposed ultralow-dose transdermal estradiol administered to postmenopausal women for 2 years...
  38. ncbi request reprint Effect of isoflavones on lipids and bone turnover markers in menopausal women
    Tamara M Knudson Schult
    Center for Chronic Disease Outcomes Research, Minneapolis VA Medical Center, MN 55417, USA
    Maturitas 48:209-18. 2004
    ..The purpose of this analysis was to compare the effects of two dietary supplements derived from red clover to placebo on lipids and bone turnover markers in symptomatic menopausal women...